NGL FINECHEM
|
NGL FINECHEM Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 77.90 | 34.19 | 66.63 | 33.04 | 80.68 |
| CEPS(Rs) | 109.60 | 54.35 | 85.72 | 51.45 | 97.55 |
| DPS(Rs) | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| Book NAV/Share(Rs) | 532.92 | 457.16 | 425.11 | 360.23 | 328.94 |
| Tax Rate(%) | 24.05 | 23.78 | 24.07 | 25.09 | 25.08 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.64 | 9.45 | 15.87 | 12.57 | 21.48 |
| EBIT Margin(%) | 13.67 | 8.41 | 16.60 | 10.50 | 21.58 |
| Pre Tax Margin(%) | 12.65 | 7.53 | 16.07 | 9.84 | 20.98 |
| PAT Margin (%) | 9.61 | 5.74 | 12.20 | 7.37 | 15.72 |
| Cash Profit Margin (%) | 13.52 | 9.12 | 15.64 | 11.43 | 18.98 |
| Performance Ratios | |||||
| ROA(%) | 9.60 | 5.30 | 12.86 | 7.27 | 20.61 |
| ROE(%) | 15.74 | 7.75 | 17.03 | 9.63 | 27.90 |
| ROCE(%) | 16.88 | 9.44 | 20.38 | 11.96 | 33.91 |
| Asset Turnover(x) | 1.00 | 0.92 | 1.05 | 0.99 | 1.31 |
| Sales/Fixed Asset(x) | 2.12 | 2.02 | 2.36 | 2.07 | 2.82 |
| Working Capital/Sales(x) | 3.96 | 3.19 | 2.69 | 2.66 | 2.94 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.47 | 0.50 | 0.42 | 0.48 | 0.36 |
| Receivable days | 77.86 | 85.47 | 83.78 | 85.22 | 58.36 |
| Inventory Days | 44.28 | 46.87 | 37.88 | 54.47 | 53.95 |
| Payable days | 88.92 | 101.53 | 85.07 | 75.67 | 72.38 |
| Valuation Parameters | |||||
| PER(x) | 26.59 | 32.59 | 31.37 | 36.22 | 24.27 |
| PCE(x) | 18.90 | 20.51 | 24.38 | 23.26 | 20.07 |
| Price/Book(x) | 3.89 | 2.44 | 4.92 | 3.32 | 5.95 |
| Yield(%) | 0.08 | 0.16 | 0.08 | 0.15 | 0.09 |
| EV/Net Sales(x) | 2.79 | 2.07 | 3.91 | 2.73 | 3.90 |
| EV/Core EBITDA(x) | 15.86 | 17.52 | 19.50 | 18.74 | 15.70 |
| EV/EBIT(x) | 20.39 | 24.56 | 23.54 | 25.99 | 18.08 |
| EV/CE(x) | 3.09 | 2.11 | 4.46 | 2.98 | 4.47 |
| M Cap / Sales | 2.55 | 1.87 | 3.81 | 2.66 | 3.81 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 36.03 | 8.73 | 21.80 | -12.42 | 23.08 |
| Core EBITDA Growth(%) | 102.84 | -36.02 | 67.63 | -48.67 | -10.49 |
| EBIT Growth(%) | 121.16 | -44.92 | 92.58 | -57.38 | -14.14 |
| PAT Growth(%) | 127.83 | -48.87 | 101.58 | -58.92 | -12.03 |
| EPS Growth(%) | 127.83 | -48.68 | 101.66 | -59.05 | -11.91 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.37 | 0.27 | 0.13 | 0.15 | 0.15 |
| Current Ratio(x) | 1.78 | 1.97 | 2.46 | 2.79 | 2.64 |
| Quick Ratio(x) | 1.35 | 1.54 | 1.96 | 2.33 | 1.79 |
| Interest Cover(x) | 13.36 | 9.51 | 31.07 | 15.92 | 35.81 |
| Total Debt/Mcap(x) | 0.10 | 0.11 | 0.03 | 0.04 | 0.02 |
Compare Financial Ratios of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,789.2 Cr | -2.5% | -11.2% | 96.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,994.0 Cr | -0% | -4.5% | 15.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹240,249.0 Cr | 5.9% | 16.1% | 49.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,135.0 Cr | 3% | 3% | 34% | Stock Analytics | |
| CIPLA | ₹114,708.0 Cr | -0.4% | -3.6% | -11.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.9 Cr | NA | 2.8% | -7.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -2.5% |
-11.2% |
96.5% |
| SENSEX | -0.8% |
0.2% |
-6% |
You may also like the below Video Courses
